Singapore Institute of Advanced Medicine Holdings (SAM) has partnered with ProNova Solutions to establish new proton therapy facility in Singapore.

ProNova will install its SC360 proton therapy system at the newly proposed $100m cancer and proton center in Biopolis campus, Singapore.

The company will equip the new center with two superconducting gantry proton treatment rooms, comprising additional room for research.

Each treatment room features Fast Scanning IMPT technology with integrated 3D imaging, which offers edge pencil beam delivery. It helps physicians and therapists to minimize collateral damage to healthy tissue and maximize dose to the tumor.

SAM founder and chairman Djeng Shih Kien said: "We believe proton therapy is a significant step forward in our treatment of cancer and ProNova has proven to be the best partner with next generation technology."

ProNova Solutions chairman and CEO Terry Douglass said the company has partnered with SAM to bring the first proton center to Singapore.

"We look forward to providing our unique total solutions offerings and sharing our proton therapy knowledge and clinical experience with SAM’s staff," Douglass added.

Biopolis campus also includes R&D centres of pharma companies such as Abbott, GlaxoSmithKline, Lilly, Novartis, Schering-Plough and Takeda.

Proton therapy is a form of radiation therapy, which uses a single beam of high-energy protons to treat different forms of cancer.